Free Trial

Keros Therapeutics (KROS) 10K Form and Latest SEC Filings 2026

Keros Therapeutics logo
$11.68 -0.10 (-0.86%)
As of 03:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Keros Therapeutics SEC Filings & Recent Activity

Keros Therapeutics (NASDAQ:KROS) has submitted 311+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Keros Therapeutics's financial statements. The most recent filing was a Form DEFA14A submitted on April 22, 2026.

Form 4
Keros Therapeutics, Inc. Reports Ownership Change on Apr. 17, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Keros Therapeutics Files Current Report on Mar. 9, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Keros Therapeutics SEC Filing History

Browse Keros Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/22/2026 3:01 PM
Keros Therapeutics (1664710) Filer
Form DEF 14A
04/22/2026 3:03 PM
Keros Therapeutics (1664710) Filer
Form DEFA14A
04/17/2026 3:15 PM
BIENAIME JEAN JACQUES (1221590) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 11:39 AM
BlackRock, Inc. (2012383) Filed by
Keros Therapeutics (1664710) Subject
Form SCHEDULE 13G
04/06/2026 3:15 PM
Keros Therapeutics (1664710) Issuer
Seehra Jasbir (1732369) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 8:57 PM
Keros Therapeutics (1664710) Subject
ORBIMED ADVISORS LLC (1055951) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2026 3:15 PM
Cho Esther (2081460) Reporting
Keros Therapeutics (1664710) Issuer
Form 4/A
03/11/2026 3:33 PM
BIENAIME JEAN JACQUES (1221590) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 3:37 PM
Keros Therapeutics (1664710) Issuer
Newton Charles W. (1866219) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/11/2026 3:39 PM
Keros Therapeutics (1664710) Issuer
Newton Charles W. (1866219) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 7:01 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 3:02 PM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2026 3:15 PM
Keros Therapeutics (1664710) Issuer
Regnante Keith (1682068) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 3:15 PM
Cho Esther (2081460) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 3:15 PM
Keros Therapeutics (1664710) Issuer
Lerner Lorena Raquel (2081359) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 3:15 PM
Keros Therapeutics (1664710) Issuer
Seehra Jasbir (1732369) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 3:02 PM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2026 3:15 PM
Keros Therapeutics (1664710) Issuer
Seehra Jasbir (1732369) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 3:16 PM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/18/2025 3:34 PM
Keros Therapeutics (1664710) Issuer
ORBIMED ADVISORS LLC (1055951) Reporting
OrbiMed Capital GP VII LLC (1760648) Reporting
OrbiMed Genesis GP LLC (1808744) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:27 PM
GORDON CARL L (1282930) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:15 PM
Keros Therapeutics (1664710) Issuer
Knowles Julius (1808365) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 5:19 AM
Keros Therapeutics (1664710) Subject
Form SC TO-I/A
11/18/2025 3:07 PM
ExodusPoint Capital Management, LP (1736225) Filed by
Keros Therapeutics (1664710) Subject
Form SCHEDULE 13G
10/27/2025 3:05 PM
D. E. SHAW & CO, L.P. (1009268) Filed by
Keros Therapeutics (1664710) Subject
Form SCHEDULE 13G
10/22/2025 8:26 PM
Keros Therapeutics (1664710) Subject
TANG CAPITAL MANAGEMENT LLC (1232621) Filed by
Form SCHEDULE 13G
10/20/2025 5:09 AM
Keros Therapeutics (1664710) Subject
Form SC TO-I
10/17/2025 4:53 PM
Kariv Tomer (1568077) Reporting
Keros Therapeutics (1664710) Issuer
Nussbaum Ran (1609805) Reporting
Pontifax (0) Israel
Pontifax Late Stage Fund L.P. (1793769) Reporting
Pontifax Late Stage GP Ltd. (1793770) Reporting
Pontifax Management 4 G.P. (2015) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 4:36 PM
Keros Therapeutics (1664710) Subject
Pontifax Management 4 G.P. (2015) Filed by
Form SCHEDULE 13D/A
10/15/2025 12:24 PM
ADAR1 Capital Management GP, LLC (1940267) Reporting
ADAR1 Capital Management, LLC (1940272) Reporting
ADAR1 Partners, LP (1758866) Reporting
Keros Therapeutics (1664710) Issuer
Schneeberger Daniel (1861120) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 5:50 AM
ADAR1 Capital Management, LLC (1940272) Filed by
Keros Therapeutics (1664710) Subject
Form SCHEDULE 13D/A
10/15/2025 5:40 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2025 5:42 AM
Keros Therapeutics (1664710) Subject
Form SC TO-C
09/12/2025 3:45 PM
Keros Therapeutics (1664710) Subject
Rovaldi Christopher (1706040) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 7:02 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2025 3:10 PM
Keros Therapeutics (1664710) Issuer
Seehra Jasbir (1732369) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 3:15 PM
ADAR1 Capital Management, LLC (1940272) Filed by
Keros Therapeutics (1664710) Subject
Form SCHEDULE 13D/A
08/20/2025 8:50 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2025 3:32 PM
Cho Esther (2081460) Reporting
Keros Therapeutics (1664710) Issuer
Form 3
Initial statement of beneficial ownership of securities  
08/15/2025 3:34 PM
Keros Therapeutics (1664710) Issuer
Lerner Lorena Raquel (2081359) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/17/2025 7:03 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025 3:05 PM
ADAR1 Capital Management GP, LLC (1940267) Reporting
ADAR1 Capital Management, LLC (1940272) Reporting
ADAR1 Partners, LP (1758866) Reporting
Keros Therapeutics (1664710) Issuer
Schneeberger Daniel (1861120) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2025 3:51 PM
ADAR1 Capital Management GP, LLC (1940267) Reporting
ADAR1 Capital Management, LLC (1940272) Reporting
ADAR1 Partners, LP (1758866) Reporting
Keros Therapeutics (1664710) Issuer
Schneeberger Daniel (1861120) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025 6:45 AM
Kariv Tomer (1568077) Reporting
Keros Therapeutics (1664710) Issuer
Form 4/A
06/11/2025 6:30 AM
Keros Therapeutics (1664710) Issuer
Nussbaum Ran (1609805) Reporting
Form 4/A
06/09/2025 5:56 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/06/2025 3:15 PM
BIENAIME JEAN JACQUES (1221590) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
GRAY MARY ANN (1261974) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
Keros Therapeutics (1664710) Issuer
Seth Alpna (1721020) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
Keros Therapeutics (1664710) Issuer
Nussbaum Ran (1609805) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
Kariv Tomer (1568077) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
Farzan Nima (1808296) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
GORDON CARL L (1282930) Reporting
Keros Therapeutics (1664710) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:15 PM
Keros Therapeutics (1664710) Issuer
Knowles Julius (1808365) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2025 5:58 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/27/2025 12:49 PM
Keros Therapeutics (1664710) Filer
Form DEFA14A
05/19/2025 7:00 AM
Keros Therapeutics (1664710) Filer
Form DEFA14A
05/19/2025 7:01 AM
Keros Therapeutics (1664710) Filer
Form DEFA14A
05/19/2025 7:02 AM
Keros Therapeutics (1664710) Filer
Form DEFA14A
05/14/2025 4:49 PM
Keros Therapeutics (1664710) Subject
Madison Avenue Partners, LP (1801265) Filed by
Form SCHEDULE 13G
05/12/2025 10:29 AM
ADAR1 Capital Management, LLC (1940272) Filed by
Keros Therapeutics (1664710) Subject
Form SCHEDULE 13D/A
05/12/2025 7:01 AM
Keros Therapeutics (1664710) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Keros Therapeutics SEC Filings - Frequently Asked Questions

Keros Therapeutics (KROS) has submitted 311+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Keros Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Keros Therapeutics's financial statements page.

The most recent filing was a Form DEFA14A submitted on April 22, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KROS) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners